Aveanna Healthcare (AVAH) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $505 million, up 7% year-over-year, driven by growth in Private Duty Services (PDS) and Medical Solutions (MS) segments.

• Adjusted EBITDA for Q2 was $45.6 million, a 27.3% increase, while net income declined to $13.9 million due to lower derivative gains and higher interest expense.

• Operating income for Q2 was $37.1 million, nearly flat year-over-year.

• Strategic focus remains on preferred payer partnerships, legislative rate improvements, and operational efficiencies.

• Full-year 2024 outlook raised, with revenue expected above $1.985 billion and adjusted EBITDA above $158 million.

Financial highlights

• PDS revenue grew 8% to $408 million, with a 4.8% increase in care hours and a 3.2% rise in revenue per hour.

• Medical Solutions revenue increased 9.3% to $42.5 million, serving 94,000 unique patients, up 10.6%.

• Home Health and Hospice revenue was $54.6 million, down 1.4%, but episodic care episodes rose 4.5% and gross margin improved by 5.2 points.

• Consolidated gross margin was $158.3 million (31.3%), with PDS at 27.2% and Medical Solutions at 42.4%.

• Field contribution margin improved to 13.9% from 13.6% year-over-year.

Outlook and guidance

• Full-year 2024 revenue projected to exceed $1.985 billion; adjusted EBITDA to surpass $158 million.

• Q3 expected to show seasonal softness in core volumes, with a rebound anticipated in Q4.

• Management expects continued growth in PDS and MS segments, supported by demand and reimbursement rate increases.

• The impact of the CMS Medicaid final rule is not expected to be material to results.

• Sufficient liquidity is anticipated for at least the next twelve months.